By the Committee on Health Care Services and Representatives Pruitt, Goode, Sanderson and Fasano

A bill to be entitled 1 2 An act relating to delivery of health care 3 services; creating a catastrophic pharmaceutical expense assistance program; 4 5 providing eligibility; prescribing duties of the Agency for Health Care Administration and 6 7 other entities; providing for rules; requiring 8 a report; requiring pharmacies that participate 9 in the program or in Medicaid to agree to 10 limitations on compensation; providing 11 legislative findings relating to health care practitioners' fiduciary responsibility to 12 13 patients and the acceptance of certain types of 14 compensation from pharmaceutical manufacturers; amending s. 455.624, F.S.; providing additional 15 16 grounds for disciplinary action against certain 17 health care practitioners; providing 18 appropriations; providing effective dates. 19 20 Be It Enacted by the Legislature of the State of Florida: 21 22 Catastrophic pharmaceutical expense Section 1. 23 assistance.--(1) PROGRAM ESTABLISHED. -- There is established a 24 program to provide financial assistance to low-income elderly 25 26 individuals with catastrophic pharmaceutical expenses. 27 ELIGIBILITY.--Eligibility is limited to those 28 individuals who do not qualify for assistance under the 29 Medicaid program and who: 30 Are over the age of 65; (a) 31

- (b) Have an income at or below 250 percent of the federal poverty level; and
- (c) Have out-of-pocket prescription expenses that exceed or are projected to exceed 10 percent of their annual income, after payments by other liable entities are deducted.
- (3) BENEFITS.--Medications covered under the catastrophic pharmaceutical expense assistance program are those covered under the Medicaid program in s. 409.906(20), Florida Statutes. Payments shall be for the total amount of prescription drug expenses above 10 percent of an individual's annual income.
- expense assistance program shall be administered by the Agency for Health Care Administration, in consultation with the Department of Elderly Affairs. To the extent possible, administration of the program, including eligibility determination, claims processing, and reporting, shall use existing administrative mechanisms, including the Medicaid fiscal agent system and area agencies on aging.
- (a) The Agency for Health Care Administration shall make payments for prescription drugs on behalf of eligible individuals.
- (b) The Agency for Health Care Administration and the Department of Elderly Affairs shall develop a single-page application for the catastrophic pharmaceutical expense assistance program.
- (c) The Agency for Health Care Administration shall, by rule, establish eligibility requirements, limits on participation, benefit limitations, a requirement for generic drug substitution, and other program parameters comparable to

those of the Medicaid program for the catastrophic pharmaceutical expense assistance program.

- (d) By January 1 of each year, the Agency for Health
 Care Administration shall report to the Legislature on the
 operation of the program. The report shall include information
 on the number of individuals served, use rates, and
 expenditures under the program. The report shall also address
 the impact of the program on reducing unmet pharmaceutical
 drug needs among the elderly and recommend programmatic
 changes.
- (5) NONENTITLEMENT.--The catastrophic pharmaceutical expense assistance program is not an entitlement and shall be the payor of last resort.

Section 2. Medicare prescription discount program.--As a condition of participation in the Florida Medicaid program or the catastrophic pharmaceutical expense assistance program, a pharmacy must agree that the charge to any Medicare beneficiary showing a Medicare card when presenting a prescription shall be no greater than the amount paid to that pharmacy for ingredients and dispensing under the Florida Medicaid program, plus 2.5 percent of the Medicaid payment for the ingredients of the prescription.

Section 3. The Legislature recognizes that the state has a compelling interest in maintaining the integrity of health care professions. The Legislature finds that health care practitioners have a fiduciary responsibility to act in the best interests of their patients, who place their trust in, and are dependent on, the professional expertise of health care practitioners when seeking their services. The Legislature finds that the nature of the relationship between the patient and the health care practitioner and the

underlying trust in that relationship prompt the need for guidelines to avoid the receipt by health care practitioners of gifts, payments, subsidies, or other financial inducements from pharmaceutical manufacturers which adversely shape the health care practitioners' independent professional judgment and which undermine their patients' access to treatment, course of care, and clinical outcomes.

Section 4. Effective October 1, 2000, paragraph (y) is added to subsection (1) of section 455.624, Florida Statutes, to read:

455.624 Grounds for discipline; penalties; enforcement.--

- (1) The following acts shall constitute grounds for which the disciplinary actions specified in subsection (2) may be taken:
- (y) Accepting gifts, payments, subsidies, or other financial inducements from pharmaceutical manufacturers which:
 - 1. Do not primarily entail a benefit to patients;
- 19 2. Are of substantial value; and
 - 3. Undermine the practitioner's independent professional judgment or which conflict with the practitioner's duty of loyalty to patients.
 - (2) When the board, or the department when there is no board, finds any person guilty of the grounds set forth in subsection (1) or of any grounds set forth in the applicable practice act, including conduct constituting a substantial violation of subsection (1) or a violation of the applicable practice act which occurred prior to obtaining a license, it may enter an order imposing one or more of the following penalties:

- (a) Refusal to certify, or to certify with restrictions, an application for a license.
 - (b) Suspension or permanent revocation of a license.
 - (c) Restriction of practice.
- (d) Imposition of an administrative fine not to exceed \$10,000 for each count or separate offense.
 - (e) Issuance of a reprimand.
- (f) Placement of the licensee on probation for a period of time and subject to such conditions as the board, or the department when there is no board, may specify. Those conditions may include, but are not limited to, requiring the licensee to undergo treatment, attend continuing education courses, submit to be reexamined, work under the supervision of another licensee, or satisfy any terms which are reasonably tailored to the violations found.
 - (g) Corrective action.
- (h) Imposition of an administrative fine in accordance with s. 381.0261 for violations regarding patient rights.

In determining what action is appropriate, the board, or department when there is no board, must first consider what sanctions are necessary to protect the public or to compensate the patient. Only after those sanctions have been imposed may the disciplining authority consider and include in the order requirements designed to rehabilitate the practitioner. All costs associated with compliance with orders issued under this subsection are the obligation of the practitioner.

Section 5. There is appropriated to the Agency for

Health Care Administration the sum of \$15,244,200 from the

Medical Care Trust Fund and the sum of \$11,755,800 from the

General Revenue Fund to provide Medicaid for services for

persons who are eligible under s. 409.904(1), Florida Statutes, and whose incomes are greater than 90 percent of the federal poverty level but no greater than 100 percent of the federal poverty level. Section 6. There is appropriated the sum of \$42 million from the General Revenue Fund to the Agency for Health Care Administration for the purpose of implementing section 1 relating to the catastrophic pharmaceutical expense assistance program. Section 7. There is appropriated the sum of \$1 million from the General Revenue Fund to the Agency for Health Care Administration to develop a computerized system that allows participating pharmacies to determine allowable maximum payments for prescription drugs under section 2. Section 8. Except as otherwise provided herein, this act shall take effect upon becoming a law.